Longevity & AgingAlzheimer's Drug PMN310 Shows Clean Safety Profile and Early Biomarker Shifts at 6 Months
ProMIS Neurosciences has shared six-month interim results from its PRECISE-AD trial testing PMN310, an antibody targeting toxic amyloid-beta oligomers in early Alzheimer's disease. Among 136 blinded patients, there were no serious treatment-related adverse events, no drug-related dropouts, and critically, no cases of brain swelling — a dangerous side effect seen with similar drugs. About 69% of patients showed a decline in a key blood-based tau marker, and 63% showed a decline in a spinal fluid tau marker, suggesting the drug may be affecting disease biology. The trial includes a high proportion of APOE4 carriers, a genetic group at elevated Alzheimer's risk. Full 12-month results are expected in early 2027.
